Hilleman CEO On $1 Rotavirus Vaccine Pricing And GSK's Mosquirix

Hilleman Laboratories' CEO, Dr Davinder Gill, believes that the venture's heat-stable rotavirus vaccine can potentially match the proposed $1 pricing of Bharat Biotech's Rotavac backed with "appropriate scale" and a robust demand forecast.